**68Ga-PSMA PET/CT mapping of early biochemical recurrence after primary surgery in 270 patients: Impact on Salvage Radiotherapy Planning**

Nicholas G. Nickols¹,², Jeremie Calais¹, Johannes Czernin³, Wolfgang P. Fendler³,⁴, Ken Herrmann³,⁵, Isabel Rauscher⁶, Nina Hegemann⁷, Thorsten Poeppel⁵, Christopher R King¹, Amar Kishan¹, John Hegde¹, Narek Shaverdian¹, Kiri Sandler¹, Robert E. Reiter⁸, Michael L. Steinberg¹, Matthew Rettig⁸,⁹, Minsong Cao¹, Matthias Eiber³,⁶

¹Department of Radiation Oncology, UCLA, Los Angeles, CA, USA
²Department of Radiation Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
³Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, USA
⁴Department of Nuclear Medicine, Ludwig-Maximilians-University Munich, Germany
⁵Department of Nuclear Medicine, Universitätsklinikum Essen, Germany
⁶Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Germany
⁷Department of Radiation Oncology, Ludwig-Maximilians-University Munich, Germany
⁸Department of Urology, UCLA, Los Angeles, CA, USA
⁹Department of Medicine, Division of Hematology-Oncology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA

**Background/Objectives:** Target volumes for salvage prostate radiotherapy (SRT) are usually drawn in the absence of visibly recurrent disease. However, 68Ga-PSMA PET/CT detects prostate cancer recurrences with accuracy superior to conventional imaging, at PSA values low enough to impact volume delineations for routine SRT. We conducted this study to i) determine how often volumes based on the Radiation Therapy Oncology Group (RTOG) consensus guidelines cover 68Ga-PSMA PET/CT defined disease in patients with serum PSA levels <1 ng/mL after radical prostatectomy ii) map the recurrence pattern of early biochemically recurrent prostate cancer after prostatectomy, and iii) assess the potential impact of 68Ga-PSMA PET/CT on SRT.

**Methods:** This is a post-hoc analysis of an intention to treat population of 270 patients who underwent 68Ga-PSMA PET/CT in 4 institutions for biochemical recurrence after prostatectomy without prior radiotherapy at PSA<1 ng/mL. RTOG consensus clinical target volumes (consensus CTVs) that included both the prostate bed and pelvic lymph nodes (LN) were contoured on the CT portion of PET/CT by an experienced radiation oncologist blinded to the PET findings. 68Ga-PSMA PET/CT images were analyzed by an experienced nuclear medicine physician. PSMA avid lesions were compared with the consensus CTVs. PSMA avid lesions not covered by planning volumes based on the consensus CTVs were considered to have a major potential impact on treatment planning.

**Results:** The median PSA at the time of 68Ga-PSMA PET/CT was 0.48 ± 0.25 (range 0.03-1 ng/ml). 132 of 270 patients (49%) had a positive 68Ga-PSMA PET/CT study. 52 patients (19% of all patients, 39% of patients with a positive 68Ga-PSMA PET/CT) had at least one PSMA avid lesion not covered by planning based on the consensus CTVs and would have been inadequately treated using these volumes. 33 patients (12% of all patients, 25% of patients with a positive 68Ga-PSMA PET/CT) had extra-pelvic PSMA avid lesions and 19 (7% of all patients, 14% of patients with a positive 68Ga-PSMA PET/CT) had PSMA avid lesions within the pelvis but not covered by consensus CTVs.

**Conclusion:** 68Ga-PSMA PET to CT would have a major impact on SRT in 52 of 270 (19%) patients with early biochemical recurrence (PSA<1.0 ng/ml) after radical prostatectomy. This impact may justify a randomized imaging trial in a similar patient cohort offered SRT with or without 68Ga-PSMA PET/CT powered for a clinical outcome. Furthermore, in patients with a positive PSMA-PET, consensus CTVs failed to cover recurrences in 52 of 132 (39%) of patients. 33 (25%) of these 132 patients had M1 disease, a majority of which (66%) were oligometastatic M1a or M1b (1 to 5 extra-pelvic sites). The frequency of oligometastatic patients in this cohort suggests a clinical trial incorporating metastasis-directed therapy is feasible even at low PSA values if patients are imaged with PSMA-PET/CT.
Conflicts of interest and Funding Acknowledgements: Jeremie Calais is the recipient of a grant from the Fondation ARC pour la recherche sur le cancer (grant n°SAE20160604150). Johannes Czernin is the recipient of a grant from the US Department of Energy (DE SC 0012363). Wolfgang Fendler received a scholarship from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG, grant 807122). Matthias Eiber was supported by the SFB 824 (DFG Sonderforschungsbereich 824, Project B11) from the Deutsche Forschungsgemeinschaft, Bonn, Germany. Nicholas Nickols is a Prostate Cancer Foundation Young Investigator and a recipient of a VA Career Development Award (5IK2BX002520), a UCLA Prostate SPORE (4P50CA092131) Career Enhancement Award, a STOP Cancer Foundation Career Development Award, and a UCLA JCCC Seed Grant. No authors report any potential conflict of interest relevant to this abstract.